Pediatric Allergy/Immunology Associates, Dallas, TX Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2002
NCT00157079
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2002

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

immune globulin (human) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Immunologic Deficiency Syndromes (Phase 3)

Mucocutaneous Lymph Node Syndrome (Phase 3)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1